Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

Significant unmet treatment needs remain for patients with Dravet syndrome, a severe ... global footprint,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ:STOK ...

On Monday, H.C. Wainwright reaffirmed a positive outlook ... is expected to reach Phase 3 top-line data for Dravet syndrome in 2026. The reiteration of the Buy rating and price target comes ...

Advocating for her youngest daughter who has Dravet Syndrome is also a top priority ... where she graduated from H-BC and grew up on a farm near Hills. In her spare time, Jennifer likes to read, watch ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...